Stocks · News reference

NovaBridge Biosciences To Present Expanded Givastomig Safety And Efficacy Data At ESMO Congress 2026

Oct 8, 2026, 8:06 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 13, 2026, 11:13 AMBenzinga Newsdesk
NovaBridge’s Visara Plans To Develop HT006.2.2 As VIS-102, Second Clinical-Stage Program, Expanding Its Ophthalmology Portfolio Beyond Retinal Vascular Disease Into Ocular Surface Disease
Visara secures exclusive worldwide rights, excluding Greater China, from Wuhan Hiteck Biological Pharma to develop and commercialize HT006.2.2Visara plans to develop HT006.2.2 as VIS-102, its second clinical-stage
NBP
BenzingaOct 13, 2026, 11:11 AMBenzinga Newsdesk
Wuhan Hiteck Biological Pharma Enters Into Exclusive License Agreement With NovaBridge’s Visara For HT006.2.2, Investigational Next-Gen Modified rhNGF Eye Drop
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ:NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2Hiteck retains all
NBP
BenzingaSep 18, 2026, 11:51 AMBenzinga Insights
NovaBridge Biosciences H1 2026 Earnings Call: Complete Transcript
NovaBridge Biosciences (NASDAQ:NBP) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
NBP